Aytu BioScience Company Insiders
| AYTU Stock | USD 2.81 0.02 0.72% |
Aytu BioScience employs about 150 people. The company is managed by 18 executives with a total tenure of roughly 75 years, averaging almost 4.0 years of service per executive, having 8.33 employees per reported executive. Breaking down Aytu BioScience's management performance can provide insight into the firm performance.
| Joshua Disbrow CEO CEO, Director |
| Jonathan McGrael President Vice President of Commercial Operations |
Aytu |
Aytu BioScience Management Team Effectiveness
The company has return on total asset (ROA) of (0.0258) % which means that it has lost $0.0258 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4575) %, meaning that it created substantial loss on money invested by shareholders. Aytu BioScience's management efficiency ratios could be used to measure how well Aytu BioScience manages its routine affairs as well as how well it operates its assets and liabilities.Aytu BioScience Workforce Comparison
Aytu BioScience is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 7,653. Aytu BioScience claims roughly 150 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.18) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.1 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.1. Aytu BioScience Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aytu BioScience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aytu BioScience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aytu BioScience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Greg Pyszczymuka over three weeks ago Disposition of 208 shares by Greg Pyszczymuka of Aytu BioScience subject to Rule 16b-3 | ||
Gary Cantrell over a month ago Acquisition by Gary Cantrell of 20000 shares of Aytu BioScience at 1.45 subject to Rule 16b-3 | ||
Greg Pyszczymuka over three months ago Exercise or conversion by Greg Pyszczymuka of 209 shares of Aytu BioScience subject to Rule 16b-3 | ||
Greg Pyszczymuka over six months ago Exercise or conversion by Greg Pyszczymuka of 208 shares of Aytu BioScience subject to Rule 16b-3 | ||
Jain Abhinav over six months ago Acquisition by Jain Abhinav of 6500 shares of Aytu BioScience subject to Rule 16b-3 | ||
John Donofrio over six months ago Acquisition by John Donofrio of 1500 shares of Aytu BioScience subject to Rule 16b-3 | ||
Greg Pyszczymuka over six months ago Exercise or conversion by Greg Pyszczymuka of 208 shares of Aytu BioScience subject to Rule 16b-3 | ||
Nantahala Capital Management Llc over six months ago Aytu BioScience exotic insider transaction detected |
Aytu BioScience Notable Stakeholders
An Aytu BioScience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aytu BioScience often face trade-offs trying to please all of them. Aytu BioScience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aytu BioScience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joshua Disbrow | CEO, Director | Profile | |
| Jonathan McGrael | Vice President of Commercial Operations | Profile | |
| Mark CPA | Secretary CFO | Profile | |
| David Green | CFO, Treasurer, Secretary | Profile | |
| Gregory Gould | CFO, Treasurer, Secretary | Profile | |
| John Donofrio | Independent Director | Profile | |
| Carl Dockery | Independent Director | Profile | |
| Ketan Mehta | Director | Profile | |
| Gary Cantrell | Independent Director | Profile | |
| Michael Macaluso | Independent Director | Profile | |
| Steven Boyd | Director | Profile | |
| Jarrett Disbrow | COO, Director | Profile | |
| Russ McMahen | Senior Development | Profile | |
| Christopher Brooke | Chief Officer | Profile | |
| Victoria Cordova | Vice Culture | Profile | |
| Topher Brooke | Chief Officer | Profile | |
| Greg Pyszczymuka | Chief Officer | Profile | |
| Ryan CPA | Executive Optimization | Profile |
About Aytu BioScience Management Performance
The success or failure of an entity such as Aytu BioScience often depends on how effective the management is. Aytu BioScience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aytu management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aytu management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado. Aytu Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 164 people.
The data published in Aytu BioScience's official financial statements usually reflect Aytu BioScience's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Aytu BioScience. For example, before you start analyzing numbers published by Aytu accountants, it's critical to develop an understanding of what Aytu BioScience's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Aytu BioScience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aytu BioScience's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Aytu BioScience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aytu BioScience. Please utilize our Beneish M Score to check the likelihood of Aytu BioScience's management manipulating its earnings.
Aytu BioScience Workforce Analysis
Traditionally, organizations such as Aytu BioScience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aytu BioScience within its industry.Aytu BioScience Manpower Efficiency
Return on Aytu BioScience Manpower
| Revenue Per Employee | 716K | |
| Revenue Per Executive | 6M | |
| Net Loss Per Employee | 113.7K | |
| Net Loss Per Executive | 947.3K | |
| Working Capital Per Employee | 25.4K | |
| Working Capital Per Executive | 212.1K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aytu BioScience. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Aytu Stock please use our How to Invest in Aytu BioScience guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Aytu Stock analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Aytu BioScience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aytu BioScience. If investors know Aytu will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aytu BioScience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aytu BioScience is measured differently than its book value, which is the value of Aytu that is recorded on the company's balance sheet. Investors also form their own opinion of Aytu BioScience's value that differs from its market value or its book value, called intrinsic value, which is Aytu BioScience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aytu BioScience's market value can be influenced by many factors that don't directly affect Aytu BioScience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aytu BioScience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aytu BioScience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aytu BioScience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.